TY - JOUR AU - Bonnet, D. AU - Dick, J. E. PY - 1997 DA - 1997// TI - Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell JO - Nat Med VL - 3 UR - https://doi.org/10.1038/nm0797-730 DO - 10.1038/nm0797-730 ID - Bonnet1997 ER - TY - JOUR AU - Tang, C. AU - Ang, B. T. AU - Pervaiz, S. PY - 2007 DA - 2007// TI - Cancer stem cell: target for anti-cancer therapy JO - FASEB J VL - 21 UR - https://doi.org/10.1096/fj.07-8560rev DO - 10.1096/fj.07-8560rev ID - Tang2007 ER - TY - BOOK PY - 2007 DA - 2007// TI - Acute Myelogenous Leukemia PB - Totowa CY - Humana Press ID - ref3 ER - TY - JOUR AU - ten Cate, B. PY - 2010 DA - 2010// TI - Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology JO - Curr Drug Targets VL - 11 UR - https://doi.org/10.2174/138945010790031063 DO - 10.2174/138945010790031063 ID - ten Cate2010 ER - TY - JOUR AU - ten Cate, B. PY - 2009 DA - 2009// TI - A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability JO - Leukemia VL - 23 UR - https://doi.org/10.1038/leu.2009.34 DO - 10.1038/leu.2009.34 ID - ten Cate2009 ER - TY - JOUR AU - Milligan, D. W. PY - 2006 DA - 2006// TI - Guidelines on the management of acute myeloid leukaemia in adults JO - Br J Haematol VL - 135 UR - https://doi.org/10.1111/j.1365-2141.2006.06314.x DO - 10.1111/j.1365-2141.2006.06314.x ID - Milligan2006 ER - TY - JOUR AU - Leith, C. P. PY - 1997 DA - 1997// TI - Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study JO - Blood VL - 89 ID - Leith1997 ER - TY - JOUR AU - Sievers, E. L. PY - 1999 DA - 1999// TI - Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate JO - Blood VL - 93 ID - Sievers1999 ER - TY - JOUR AU - Sievers, E. L. PY - 2001 DA - 2001// TI - Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse JO - J Clin Oncol VL - 19 ID - Sievers2001 ER - TY - JOUR AU - Larson, R. A. PY - 2005 DA - 2005// TI - Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence JO - Cancer VL - 104 UR - https://doi.org/10.1002/cncr.21326 DO - 10.1002/cncr.21326 ID - Larson2005 ER - TY - JOUR AU - Lowenberg, B. PY - 2010 DA - 2010// TI - Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study JO - Blood VL - 115 UR - https://doi.org/10.1182/blood-2009-10-246470 DO - 10.1182/blood-2009-10-246470 ID - Lowenberg2010 ER - TY - JOUR AU - Walter, R. B. PY - 2007 DA - 2007// TI - CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy JO - Blood VL - 109 UR - https://doi.org/10.1182/blood-2006-09-047399 DO - 10.1182/blood-2006-09-047399 ID - Walter2007 ER - TY - JOUR AU - Jawad, M. PY - 2010 DA - 2010// TI - Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia JO - Leukemia VL - 24 UR - https://doi.org/10.1038/leu.2009.199 DO - 10.1038/leu.2009.199 ID - Jawad2010 ER - TY - JOUR AU - Zhao, X. PY - 2010 DA - 2010// TI - Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia JO - Haematologica VL - 95 UR - https://doi.org/10.3324/haematol.2009.009811 DO - 10.3324/haematol.2009.009811 ID - Zhao2010 ER - TY - JOUR AU - van Rhenen, A. PY - 2007 DA - 2007// TI - The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells JO - Blood VL - 110 UR - https://doi.org/10.1182/blood-2007-03-083048 DO - 10.1182/blood-2007-03-083048 ID - van Rhenen2007 ER - TY - JOUR AU - Tang, R. PY - 2008 DA - 2008// TI - Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML) JO - BMC Cancer VL - 8 UR - https://doi.org/10.1186/1471-2407-8-51 DO - 10.1186/1471-2407-8-51 ID - Tang2008 ER - TY - JOUR AU - Latagliata, R. PY - 2008 DA - 2008// TI - Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia JO - Br J Haematol VL - 143 UR - https://doi.org/10.1111/j.1365-2141.2008.07400.x DO - 10.1111/j.1365-2141.2008.07400.x ID - Latagliata2008 ER - TY - BOOK AU - Robert, G. AU - Fenton, D. L. L. PY - 2008 DA - 2008// TI - Cancer Cell Biology and Angiogenesis PB - The McGraw-Hill Companies CY - Inc ID - Robert2008 ER - TY - JOUR AU - Martelli, A. M. PY - 2010 DA - 2010// TI - The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis JO - Histol Histopathol VL - 25 ID - Martelli2010 ER - TY - JOUR AU - Martelli, A. M. PY - 2009 DA - 2009// TI - Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia JO - Expert Opin Investig Drugs VL - 18 UR - https://doi.org/10.1517/14728220903136775 DO - 10.1517/14728220903136775 ID - Martelli2009 ER - TY - STD TI - Sirolimus. ID - ref21 ER - TY - JOUR AU - Bleau, A. M. PY - 2009 DA - 2009// TI - PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells JO - Cell Stem Cell VL - 4 UR - https://doi.org/10.1016/j.stem.2009.01.007 DO - 10.1016/j.stem.2009.01.007 ID - Bleau2009 ER - TY - JOUR AU - Goodell, M. A. PY - 1996 DA - 1996// TI - Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo JO - J Exp Med VL - 183 UR - https://doi.org/10.1084/jem.183.4.1797 DO - 10.1084/jem.183.4.1797 ID - Goodell1996 ER - TY - BOOK PY - 2009 DA - 2009// TI - Cancer Stem Cells: Identification and Targets PB - Hoboken CY - Sons ID - ref24 ER - TY - JOUR AU - Yuan, T. L. AU - Cantley, L. C. PY - 2008 DA - 2008// TI - PI3K pathway alterations in cancer: variations on a theme JO - Oncogene VL - 27 UR - https://doi.org/10.1038/onc.2008.245 DO - 10.1038/onc.2008.245 ID - Yuan2008 ER - TY - JOUR AU - Muranyi, A. L. AU - Dedhar, S. AU - Hogge, D. E. PY - 2010 DA - 2010// TI - Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors JO - Leuk Res VL - 34 UR - https://doi.org/10.1016/j.leukres.2010.01.006 DO - 10.1016/j.leukres.2010.01.006 ID - Muranyi2010 ER - TY - JOUR AU - Courtney, K. D. AU - Corcoran, R. B. AU - Engelman, J. A. PY - 2010 DA - 2010// TI - The PI3K pathway as drug target in human cancer JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.25.3641 DO - 10.1200/JCO.2009.25.3641 ID - Courtney2010 ER - TY - JOUR AU - Hess, G. PY - 2009 DA - 2009// TI - Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.20.7977 DO - 10.1200/JCO.2008.20.7977 ID - Hess2009 ER - TY - JOUR AU - Hainsworth, J. D. PY - 2010 DA - 2010// TI - Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.26.3152 DO - 10.1200/JCO.2009.26.3152 ID - Hainsworth2010 ER - TY - JOUR AU - Ghobrial, I. M. PY - 2010 DA - 2010// TI - Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.24.0994 DO - 10.1200/JCO.2009.24.0994 ID - Ghobrial2010 ER - TY - JOUR AU - Pandolfi, P. P. PY - 2004 DA - 2004// TI - Breast cancer--loss of PTEN predicts resistance to treatment JO - N Engl J Med VL - 351 UR - https://doi.org/10.1056/NEJMcibr043143 DO - 10.1056/NEJMcibr043143 ID - Pandolfi2004 ER - TY - JOUR AU - Peng, C. PY - 2010 DA - 2010// TI - PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice JO - Blood VL - 115 UR - https://doi.org/10.1182/blood-2009-06-228130 DO - 10.1182/blood-2009-06-228130 ID - Peng2010 ER - TY - JOUR AU - Von Hoff, D. D. PY - 2009 DA - 2009// TI - Inhibition of the hedgehog pathway in advanced basal-cell carcinoma JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0905360 DO - 10.1056/NEJMoa0905360 ID - Von Hoff2009 ER - TY - JOUR AU - Rudin, C. M. PY - 2009 DA - 2009// TI - Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449 JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0902903 DO - 10.1056/NEJMoa0902903 ID - Rudin2009 ER - TY - JOUR AU - Hofmann, I. PY - 2009 DA - 2009// TI - Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis JO - Cell Stem Cell VL - 4 UR - https://doi.org/10.1016/j.stem.2009.03.016 DO - 10.1016/j.stem.2009.03.016 ID - Hofmann2009 ER - TY - JOUR AU - Fang, J. AU - Seki, T. AU - Maeda, H. PY - 2009 DA - 2009// TI - Therapeutic strategies by modulating oxygen stress in cancer and inflammation JO - Adv Drug Deliv Rev VL - 61 UR - https://doi.org/10.1016/j.addr.2009.02.005 DO - 10.1016/j.addr.2009.02.005 ID - Fang2009 ER - TY - JOUR AU - Kotamraju, S. AU - Williams, C. L. AU - Kalyanaraman, B. PY - 2007 DA - 2007// TI - Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-07-0993 DO - 10.1158/0008-5472.CAN-07-0993 ID - Kotamraju2007 ER - TY - CHAP AU - Chen, R. PY - 2010 DA - 2010// TI - Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death BT - Med Oncol ID - Chen2010 ER - TY - JOUR AU - Li, R. PY - 2010 DA - 2010// TI - P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells JO - ACS Nano VL - 4 UR - https://doi.org/10.1021/nn9011225 DO - 10.1021/nn9011225 ID - Li2010 ER - TY - JOUR AU - Li, G. Y. PY - 2009 DA - 2009// TI - Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia JO - Biomed Pharmacother VL - 63 UR - https://doi.org/10.1016/j.biopha.2008.10.008 DO - 10.1016/j.biopha.2008.10.008 ID - Li2009 ER - TY - JOUR AU - Balyasnikova, I. V. PY - 2010 DA - 2010// TI - Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma JO - PLoS One VL - 5 UR - https://doi.org/10.1371/journal.pone.0009750 DO - 10.1371/journal.pone.0009750 ID - Balyasnikova2010 ER - TY - JOUR AU - Wei, Z. PY - 2009 DA - 2009// TI - Bone marrow mesenchymal stem cells from leukemia patients inhibit growth and apoptosis in serum-deprived K562 cells JO - J Exp Clin Cancer Res VL - 28 UR - https://doi.org/10.1186/1756-9966-28-141 DO - 10.1186/1756-9966-28-141 ID - Wei2009 ER - TY - JOUR AU - Mishima, K. PY - 2001 DA - 2001// TI - Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor JO - Cancer Res VL - 61 ID - Mishima2001 ER - TY - JOUR AU - Morrison, R. PY - 2011 DA - 2011// TI - Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis JO - J Oncol VL - 2011 UR - https://doi.org/10.1155/2011/941876 DO - 10.1155/2011/941876 ID - Morrison2011 ER -